c-Met inhibitor 1 is primarily used in cancer research and therapy development. It targets the c-Met receptor tyrosine kinase, which is often implicated in tumor growth, metastasis, and angiogenesis. By inhibiting this receptor, the compound helps in blocking signaling pathways that promote cancer cell survival and proliferation. It is particularly studied in cancers where c-Met is overexpressed or mutated, such as hepatocellular carcinoma, gastric cancer, and non-small cell lung cancer. Researchers utilize it to understand tumor biology and to develop targeted therapies that can improve treatment outcomes for patients with resistant or advanced cancers. Additionally, it serves as a tool compound in preclinical studies to evaluate the efficacy of c-Met inhibition in combination with other anticancer agents.